Zafgen

ZFGN NASDAQ
1.040
-0.110
-9.57%
Closed 18:04 07/22 EDT
Open
1.160
Prev Close
1.150
High
1.180
Low
1.030
Volume
340.76K
Avg Vol (3M)
317.46K
52 Week High
12.36
52 Week Low
1.030
% Turnover
0.91%
Market Cap
38.82M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Zafgen ZFGN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company uses its proprietary methionine aminopeptidase 2 (MetAP2) biology platform to develop novel therapies for patients affected by complex metabolic diseases. Its product candidate is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor that is used to treat type 2 diabetes and other related metabolic disorders. Type 2 diabetes is a prevalent, chronic, progressive and multifactorial disorder that leads to increased microvascular and macrovascular disease and as such increases risk of death from cardiovascular disease, stroke, and kidney failure. Its MetAP2 development candidate ZGN-1258 is administered by subcutaneous injection. ZGN-1258 is used for the treatment of Prader-Willi syndrome (PWS). PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms including hyperphagia, uncontrollable hunger and its related behaviors, and obesity.
MORE >

Recently

Name
Price
%Change